{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:01:31Z","timestamp":1789927291838,"version":"4.0.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T00:00:00Z","timestamp":1411084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T00:00:00Z","timestamp":1411084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2014.66","type":"journal-article","created":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T13:16:56Z","timestamp":1411132616000},"page":"e247-e247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion"],"prefix":"10.1038","volume":"4","author":[{"given":"A","family":"Maurizot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-P","family":"Beressi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Man\u00e9glier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N H","family":"de la Marre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Spentchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Soury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Solvet-Sebire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Collet-Gaudillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-M","family":"Baud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Livarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,19]]},"reference":[{"key":"BFbcj201466_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ajh.22037","volume":"86","author":"KJ Aichberger","year":"2011","unstructured":"Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011; 86: 533\u2013539.","journal-title":"Am J Hematol"},{"key":"BFbcj201466_CR2","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/jnci\/djr292","volume":"103","author":"P Le Coutre","year":"2011","unstructured":"Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 2011; 103: 1347\u20131348.","journal-title":"J Natl Cancer Inst"},{"key":"BFbcj201466_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","volume":"12","author":"A Quintas-Cardama","year":"2012","unstructured":"Quintas-Cardama A, Kantarjian H, Cortes J . Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012; 12: 337\u2013340.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFbcj201466_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/ajh.22051","volume":"86","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Letendre L . Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol 2011; 86: 610\u2013611.","journal-title":"Am J Hematol"},{"key":"BFbcj201466_CR5","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197\u20132203.","journal-title":"Leukemia"},{"key":"BFbcj201466_CR6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841\u2013851.","journal-title":"Lancet Oncol"},{"key":"BFbcj201466_CR7","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/leu.2013.69","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013; 27: 1310\u20131315.","journal-title":"Leukemia"},{"key":"BFbcj201466_CR8","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/leu.2013.70","volume":"27","author":"TD Kim","year":"2013","unstructured":"Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or Imatinib. Leukemia 2013; 27: 1316\u20131321.","journal-title":"Leukemia"},{"key":"BFbcj201466_CR9","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.3324\/haematol.2013.086355","volume":"98","author":"Z Racil","year":"2013","unstructured":"Racil Z, Razga F, Drapalova J, Buresova L, Zackova D, Palackova M et al. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica 2013; 98: e124\u2013e126.","journal-title":"Haematologica"},{"key":"BFbcj201466_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129\u2013141.","journal-title":"Cancer Cell"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201466.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201466","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201466.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T22:57:12Z","timestamp":1672959432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,19]]},"references-count":10,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,9]]}},"alternative-id":["BFbcj201466"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2014.66","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,19]]},"assertion":[{"value":"19 September 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PR received a research grant from Novartis. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}